UCB Cuts $2.1 Billion Deal to Acquire Ra Pharma
UCB Cuts $2.1 Billion Deal to Acquire Ra Pharma
The move will allow the Belgium-headquartered biopharmaceutical giant to boost its work on treatments for rare diseases.
UCB Cuts $2.1 Billion Deal to Acquire Ra Pharma
UCB Cuts $2.1 Billion Deal to Acquire Ra Pharma

The move will allow the Belgium-headquartered biopharmaceutical giant to boost its work on treatments for rare diseases.

The move will allow the Belgium-headquartered biopharmaceutical giant to boost its work on treatments for rare diseases.

drug development
Cancer Drugs in Development May Be Targeting Wrong Proteins
Cancer Drugs in Development May Be Targeting Wrong Proteins
Shawna Williams | Sep 12, 2019
A study of 11 drugs now in clinical trials suggests they do kill cancer cells—but through a different mechanism than indicated in previous research.
Laskers Go to Immunologists, Developers of Breast Cancer Therapy
Laskers Go to Immunologists, Developers of Breast Cancer Therapy
Jef Akst | Sep 10, 2019
The 2019 Lasker medical and research awards celebrate advances in scientists’ understanding of T and B cells, Herceptin antibodies for treating breast cancer, and vaccine coverage around the globe.
Recent Trials for Fragile X Syndrome Offer Hope
Recent Trials for Fragile X Syndrome Offer Hope
Randi Hagerman | Sep 1, 2019
Despite a solid understanding of the biological basis of fragile X syndrome, researchers have struggled to develop effective treatments.
First New Tuberculosis Drug Approved in 50 Years
First New Tuberculosis Drug Approved in 50 Years
Jef Akst | Aug 15, 2019
The US Food and Drug Administration green lights a therapy for an extreme form of multidrug resistant TB.
Leaders of AveXis Out Over Doctored Gene Therapy Data
Leaders of AveXis Out Over Doctored Gene Therapy Data
Kerry Grens | Aug 14, 2019
Novartis, which bought the biotech firm in 2018, announced that the company’s top scientists have left, and news reports say it’s because they were involved in using manipulated data to get the gene therapy Zolgensma approved.
Infographic: Gut Microbes Change How Well Drugs Work
Infographic: Gut Microbes Change How Well Drugs Work
Shawna Williams | Jul 15, 2019
Our resident bacteria can affect the activity of immunotherapies and other medicines in the body.
Table: Personalized Cancer Vaccine Trials in the United States
Table: Personalized Cancer Vaccine Trials in the United States
Jasreet Hundal, Elaine R. Mardis | Jul 15, 2019
There are currently more than two dozen ongoing Phase 1 and Phase 2 trials using different vaccine platforms such as DNA, RNA, synthetic long peptides, and dendritic cells.
How the Microbiome Influences Drug Action
How the Microbiome Influences Drug Action
Shawna Williams | Jul 15, 2019
Through their effects on metabolism and immunity, bacteria in the gut affect whether medications will be effective for a given patient.
Potential Causes of Irreproducibility Revealed
Potential Causes of Irreproducibility Revealed
Abby Olena | Jul 11, 2019
Five independent groups got different results in a drug-response experiment, despite sharing protocols, reagents, and cell lines. The researchers identify technical variables that could be to blame.